Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Cytek Biosciences (CTKB) Long-Term Debt Repayments (2022 - 2026)

Cytek Biosciences filings provide 4 years of Long-Term Debt Repayments readings, the most recent being $2.9 million for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments rose 2015.11% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 million, a 751.89% increase, with the full-year FY2025 number at $4.7 million, up 751.89% from a year prior.
  • Long-Term Debt Repayments hit $2.9 million in Q4 2025 for Cytek Biosciences, up from $145000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.9 million in Q4 2025 to a low of $50000.0 in Q4 2022.
  • Median Long-Term Debt Repayments over the past 4 years was $140000.0 (2023), compared with a mean of $455153.8.
  • Biggest five-year swings in Long-Term Debt Repayments: fell 4.79% in 2024 and later skyrocketed 2015.11% in 2025.
  • Cytek Biosciences' Long-Term Debt Repayments stood at $50000.0 in 2022, then soared by 180.0% to $140000.0 in 2023, then decreased by 0.71% to $139000.0 in 2024, then skyrocketed by 2015.11% to $2.9 million in 2025.
  • The last three reported values for Long-Term Debt Repayments were $2.9 million (Q4 2025), $145000.0 (Q3 2025), and $142000.0 (Q2 2025) per Business Quant data.